Therapeutic strategies targeting METTL3—including pharmacologic inhibition (e.g., Erianin, STM2457) and combination regimens with mTOR or immune checkpoint inhibitors—exploit its role in ccRCC’s molecular vulnerabilities. This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.